Close Menu

NEW YORK – Skin cancer diagnostics company Castle Biosciences reported after the close of the market on Thursday preliminary performance results for the fourth quarter 2019 that showed a 37 percent year-over-year increase in volume for the company's DecisionDx-Melanoma test.

For the three months ended Dec. 31, 2019, the company delivered 4,480 DecisionDx-Melanoma test reports, compared to 3,270 reports during Q4 2018. Castle also delivered 434 DecisionDx-UM test reports for uveal melanoma in Q4, up 13 percent from 385 reports in Q4 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.